Influenza virus vaccine, quadrivalent (GlaxoSmithKline)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInfluenza virus vaccine, quadrivalent (GlaxoSmithKline)
Drug Alias NameQuadrivalent influenza vaccine – GlaxoSmithKlineInflusplit Tetra 2013/2014Fluarix Tetra 2013/2014FluarixTetraInactivated quadrivalent influenza vaccine - GlaxoSmithKline +[12] 
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Split vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsInfluenza A virus infectionsInfluenza, HumanInfluenza B virus infection
Global Approved IndicationsInfluenza A virus infectionsInfluenza, HumanInfluenza B virus infection
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/11/30
Country/TerritoryCzechiaBelgiumCanada +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsInfluenza A virus infectionsInfluenza, HumanInfluenza B virus infection
Inactive IndicationsN/A

Other Information

ATC CodeJ07BB02
Related LinksN/A